United StatesIn September 2026, Paul Knoepfler, a professor of cell biology and human anatomy at UC Davis School of Medicine, discusses the FDA's handling of unproven stem cell treatments under the Trump administration. He references Robert F. Kennedy Jr.'s admission in June 2025 that he received unproven stem cell treatments in the Caribbean for his throat condition, which raised concerns about potential lax regulation of such treatments in the U.S. Despite initial worries, Knoepfler notes that the FDA has made notable progress in addressing the issue of unregulated stem cell clinics. He highlights the existence of over 2,000 such clinics in the U.S., based on a study cited in the article.
Bias read (Center): The article presents a balanced view of the FDA's regulatory actions regarding unproven stem cell treatments, acknowledging both the challenges posed by unregulated clinics and the agency's efforts to address them. It does not exhibit overtly biased language or one-sided sourcing, focusing insteadon
